In February, Congress finally took action to rein in PBMs via the Consolidated Appropriations Act of 2026. It included reforms like the delinking of PBM compensation from the price of a drug in ...

PCR is a mainstay in diagnostics, but whether a sample is collected at a clinic or at home, such tests require sending a sample to a lab and then waiting for results. A new FDA authorized ...

Trust is a major theme flowing through many of the conversations healthcare leaders are having about how to safely and effectively incorporate AI into the field, pointed out Joel Gordon, chief medical ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

Servier is expanding its cancer drug prospects through the $2.5 billion acquisition of Day One Biopharmaceuticals, a biotech with a commercialized therapy for a type of pediatric glioma and ...

Contract negotiations between Mount Sinai and Anthem Blue Cross Blue Shield broke down this week, leaving the health system completely out of Anthem’s insurance network. The dispute reflects broader ...

Though medical personnel burnout rates have begun to stabilize, they remain higher than pre-pandemic levels, and significant challenges remain. Continued efforts are needed to tackle the underlying ...

Drugs for the rare hormone disorder acromegaly include older engineered peptides administered as frequent injections. A new FDA approval brings acromegaly patients the choice of a once-daily pill that ...

Grow Therapy's Series D funding was led by TCV and Growth Equity at Goldman Sachs Alternatives, with participation from BCI, Menlo Ventures, Sequoia, SignalFire and Transformation Capital.

Contraline — a trailblazer in the nascent male contraceptive market — released promising new trial data on Thursday showing that the company’s contraceptive hydrogel has demonstrated safety and ...